TABLE 2.
In vitro activities of BMS-207147, Sch56592, and voriconazole against isolates of Candida species with decreased susceptibility to fluconazole and itraconazole
| Species (no. of isolates) and antifungal agent | MIC (μg/ml)
|
||
|---|---|---|---|
| Range | 50% of isolates | 90% of isolates | |
| C. albicans (12) | |||
| BMS-207147 | 0.03–>8.0 | 0.12 | >8 |
| Sch 56592 | 0.03–>8.0 | 8.0 | >8.0 |
| Voriconazole | 0.25–>8.0 | >8.0 | >8.0 |
| Fluconazole | 64–>128 | >128 | >128 |
| Itraconazole | 1.0–>8.0 | >8.0 | >8.0 |
| C. glabrata (25) | |||
| BMS-207147 | 0.5–>8.0 | 4.0 | 8.0 |
| Sch 56592 | 1.0–>8 | 4.0 | >8.0 |
| Voriconazole | 1.0–8.0 | 4.0 | 8.0 |
| Fluconazole | 64–>128 | 128 | >128 |
| Itraconazole | 2.0–>8.0 | >8.0 | >8.0 |
| C. krusei (13) | |||
| BMS-207147 | 0.25–0.5 | 0.25 | 0.5 |
| Sch 56592 | 0.25–1.0 | 0.5 | 0.5 |
| Voriconazole | 0.25–1.0 | 0.5 | 1.0 |
| Fluconazole | 64–128 | 64 | 128 |
| Itraconazole | 1.0–2.0 | 1.0 | 2.0 |
| C. tropicalis (3) | |||
| BMS-207147 | >8.0 | >8.0 | |
| Sch 56592 | 8–>8.0 | >8.0 | |
| Voriconazole | 4–>8.0 | >8.0 | |
| Fluconazole | 128–>128 | >128 | |
| Itraconazole | >8.0 | >8.0 | |